Allarity Therapeutics A / S develops various therapeutic candidates for the treatment of cancer using complementary drug-specific diagnostics (cDx) generated by its drug response prediction technology. The company is headquartered in Horsholm, Denmark.
| Revenue (TTM) | 320,000 |
| Gross Profit (TTM) | 320,000 |
| EBITDA | $-12.60M |
| Operating Margin | -912.00% |
| Return on Equity | -103.80% |
| Return on Assets | -38.50% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $0.52 |
| Price-to-Book | 2.22 |
| Price-to-Sales (TTM) | 68.22 |
| EV/Revenue | 26.7 |
| EV/EBITDA | -0.08 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $15.82M |
| Float | $15.79M |
| % Insiders | 3.45% |
| % Institutions | 7.07% |
Volatility is currently contracting